Clinical Trials | June 14, 2026
Breakthrough approval in prostate cancer for AstraZeneca therapy
The decision was driven by results from the Phase III CAPItello-281 trial,
The decision was driven by results from the Phase III CAPItello-281 trial,
The regulatory decision follows promising results from RIVER-81
Dr. Quirk said the program’s mechanism offers a targeted approach to disrupted brain signaling in compulsivity-related disorders
Company experts to participate in eight sessions covering AI-powered clinical development, regulatory innovation, oncology research, and patient engagement
The film tells the story of a 70-year-old woman from Kota, Rajasthan, whose persistent cough led to a diagnosis of advanced lung cancer
The collaboration aims to develop differentiated biologics that offer greater convenience and accessibility for patients
Collaboration aims to accelerate medicinal chemistry decision-making, reduce synthesis burden and strengthen data-secure AI adoption in drug discovery
Company may qualify for 180-day generic exclusivity as sole first applicant for Bayer’s Vitrakvi capsules in the U.S.
The company gets access to Lonza’s clinically validated SYNtecan linker-payload platform as it prepares an IND filing for its acute myeloid leukemia therapy in 2027
Consolidated entity plans to strengthen specialty pharmaceutical offerings, expand manufacturing capacity, and accelerate global market penetration across emerging regions
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
